Literature DB >> 15744489

[Intraocular inflammations. A diagnostic and therapeutic challenge].

U Pleyer1.   

Abstract

Mesh:

Substances:

Year:  2005        PMID: 15744489     DOI: 10.1007/s00347-005-1180-z

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


× No keyword cloud information.
  6 in total

Review 1.  World blindness: a 21st century perspective.

Authors:  H R Taylor; J E Keeffe
Journal:  Br J Ophthalmol       Date:  2001-03       Impact factor: 4.638

Review 2.  Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel.

Authors:  D A Jabs; J T Rosenbaum; C S Foster; G N Holland; G J Jaffe; J S Louie; R B Nussenblatt; E R Stiehm; H Tessler; R N Van Gelder; S M Whitcup; D Yocum
Journal:  Am J Ophthalmol       Date:  2000-10       Impact factor: 5.258

3.  [Cyclosporine monitoring in patients with chronic uveitis].

Authors:  S Schmidt; U Pleyer
Journal:  Ophthalmologe       Date:  2005-04       Impact factor: 1.059

4.  The rate of visual loss in Behçet's disease.

Authors:  J G Mamo
Journal:  Arch Ophthalmol       Date:  1970-10

5.  Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis.

Authors:  I Kötter; M Zierhut; A K Eckstein; R Vonthein; T Ness; I Günaydin; B Grimbacher; S Blaschke; W Meyer-Riemann; H H Peter; N Stübiger
Journal:  Br J Ophthalmol       Date:  2003-04       Impact factor: 4.638

6.  Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study.

Authors:  David C Gritz; Ira G Wong
Journal:  Ophthalmology       Date:  2004-03       Impact factor: 12.079

  6 in total
  1 in total

1.  [Monitoring treatment with biologics in non-infectious uveitis].

Authors:  T Barisani-Asenbauer
Journal:  Ophthalmologe       Date:  2011-01       Impact factor: 1.059

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.